Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | TKI-related toxicities in CML & the importance of long-term monitoring

Giuseppe Saglio, MD, University of Turin, Turin, Italy, discusses toxicities associated with tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid leukemia (CML), drawing focus on the importance of monitoring these patients in the long-term, and commenting on the financial toxicity of treatment in CML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.